
Commentary|Articles|December 11, 2014
Pembrolizumab for TNBC
Author(s)Sara A. Hurvitz, MD
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
Advertisement
Clinical Pearls
Sara Hurvitz, MD, medical oncologist, UCLA Medical Center, discusses the results of a study looking at pembrolizumab (Keytruda) in patients with triple-negative breast cancer (TNBC).
- Inhibiting the PD-1 pathway showed activity in advanced TNBC in a previous phase I study.
- In this study, a heavily pretreated population of patients with TNBC tolerated pembrolizumab well. Durable responses were observed.
- There remains a need for breast cancer doctors to understand how to manage toxicities associated with immunotherapies.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5








































